Quick Answer
Cytosorbents Corp reported Operating Income Loss of -$14.75 million for the year ending 2025.
- Cytosorbents Corp showed an increase of +10.4% in Operating Income Loss from 2024 to 2025.
- This data is from Cytosorbents Corp's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Cytosorbents Corp's Operating Income Loss has declined by 422.3%.
- Historical annual values: Fiscal year 2025: -$14.75 million | Fiscal year 2024: -$16.45 million | Fiscal year 2023: -$31.95 million | Fiscal year 2022: -$31.52 million | Fiscal year 2021: -$22.74 million | Fiscal year 2020: -$10.37 million | Fiscal year 2019: -$18.97 million | Fiscal year 2018: -$15.58 million | Fiscal year 2017: -$9.84 million | Fiscal year 2016: -$11.49 million | Fiscal year 2015: -$9.30 million | Fiscal year 2014: -$6.89 million | Fiscal year 2013: -$4.71 million | Fiscal year 2012: -$3.49 million | Fiscal year 2011: -$4.44 million | Fiscal year 2010: -$2.82 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: